JP6898306B2 - Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 - Google Patents

Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 Download PDF

Info

Publication number
JP6898306B2
JP6898306B2 JP2018507641A JP2018507641A JP6898306B2 JP 6898306 B2 JP6898306 B2 JP 6898306B2 JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018507641 A JP2018507641 A JP 2018507641A JP 6898306 B2 JP6898306 B2 JP 6898306B2
Authority
JP
Japan
Prior art keywords
group
mmol
lcms
esi
grams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018507641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531218A (ja
JP2018531218A5 (OSRAM
JP2018531218A6 (ja
Inventor
シュホエイ チェン
シュホエイ チェン
チョンシア チェン
チョンシア チェン
メイビ ダイ
メイビ ダイ
チェン シエ
チェン シエ
ペン リ
ペン リ
ヤン チャン
ヤン チャン
グイバイ リャン
グイバイ リャン
チアン ワン
チアン ワン
チアンペン リャオ
チアンペン リャオ
フェイ スン
フェイ スン
クオピン フ
クオピン フ
チエン リ
チエン リ
Original Assignee
ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド
ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド, ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド filed Critical ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド
Publication of JP2018531218A publication Critical patent/JP2018531218A/ja
Publication of JP2018531218A6 publication Critical patent/JP2018531218A6/ja
Publication of JP2018531218A5 publication Critical patent/JP2018531218A5/ja
Application granted granted Critical
Publication of JP6898306B2 publication Critical patent/JP6898306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018507641A 2015-08-07 2016-08-03 Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 Active JP6898306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510484124.6 2015-08-07
CN201510484124 2015-08-07
CN201510908082 2015-12-09
CN201510908082.4 2015-12-09
PCT/CN2016/092989 WO2017024968A1 (zh) 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物

Publications (4)

Publication Number Publication Date
JP2018531218A JP2018531218A (ja) 2018-10-25
JP2018531218A6 JP2018531218A6 (ja) 2018-12-13
JP2018531218A5 JP2018531218A5 (OSRAM) 2019-09-19
JP6898306B2 true JP6898306B2 (ja) 2021-07-07

Family

ID=57983012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507641A Active JP6898306B2 (ja) 2015-08-07 2016-08-03 Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物

Country Status (5)

Country Link
US (1) US10519133B2 (OSRAM)
EP (1) EP3333157B1 (OSRAM)
JP (1) JP6898306B2 (OSRAM)
CN (1) CN107922349B (OSRAM)
WO (1) WO2017024968A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6803410B2 (ja) * 2017-02-14 2020-12-23 富士フイルム株式会社 インダゾール化合物の製造方法およびインダゾール化合物
JP6974618B2 (ja) * 2017-12-07 2021-12-01 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ及びｖｅｇｆｒ阻害剤としての化合物の塩形態、結晶形およびその製造方法
CN113490667B (zh) * 2018-12-29 2023-10-27 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
KR102754529B1 (ko) * 2019-02-02 2025-01-14 노바온코 제이에스 테라퓨틱스 컴퍼니 리미티드 Pd-l1 면역조절제인 플루오로 비닐 벤즈아미드 화합물
WO2020156564A1 (zh) 2019-02-02 2020-08-06 南京明德新药研发有限公司 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
CA3141424C (en) * 2019-06-14 2023-11-07 Zhengxia CHEN Fused ring compound as fgfr and vegfr dual inhibitor
EP4056558A4 (en) * 2019-11-06 2023-12-27 Jinan University INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4186894B1 (en) * 2020-08-11 2024-12-04 Henan Medinno Pharmaceutical Technology Co., Ltd. Fgfr inhibitor compound and use thereof
AU2021401741A1 (en) * 2020-12-17 2023-06-29 Blossomhill Therapeutics, Inc. Macrocycles and their use
PE20240687A1 (es) * 2020-12-30 2024-04-10 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
CN116761798A (zh) * 2020-12-30 2023-09-15 泰拉生物科学公司 作为激酶抑制剂的吲唑类化合物
WO2023279041A1 (en) * 2021-06-30 2023-01-05 Tyra Biosciences, Inc. Indazole compounds
CA3259217A1 (en) * 2022-06-29 2024-01-04 Tyra Biosciences Inc INDAZOLE COMPOUNDS
CN116239623B (zh) * 2022-11-18 2025-11-18 江西亚太科技发展有限公司 一种硼酸酯的制备方法及其应用
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010137A1 (en) * 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
AU2003289287A1 (en) 2002-12-03 2004-06-23 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
BR0317548A (pt) * 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
AR078411A1 (es) * 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende

Also Published As

Publication number Publication date
JP2018531218A (ja) 2018-10-25
CN107922349A (zh) 2018-04-17
WO2017024968A1 (zh) 2017-02-16
EP3333157A1 (en) 2018-06-13
US10519133B2 (en) 2019-12-31
EP3333157B1 (en) 2020-12-23
EP3333157A4 (en) 2018-10-17
CN107922349B (zh) 2021-05-07
US20180222886A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
JP6898306B2 (ja) Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
JP2018531218A6 (ja) Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
JP7377798B2 (ja) ｃ－ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物
US10654808B2 (en) Tyrosine kinase inhibitor and pharmaceutical composition comprising same
JP7233410B2 (ja) Ｅｇｆｒキナーゼ阻害薬としてのアリールホスフィンオキシド
JP6600365B2 (ja) Ｊａｋ阻害剤
TWI819470B (zh) Fgfr激酶抑制劑及其應用
KR20190110103A (ko) Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도
JP2016537369A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
JP2017519821A (ja) ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミドン類似体
JP7050054B2 (ja) Ｐｄｅ４阻害剤としての縮合環系化合物
CN109311908B (zh) 作为Akt抑制剂的二氢吡唑氮杂卓类化合物
CN107614501B (zh) 羟基嘌呤类化合物及其应用
JP7063899B2 (ja) Ｆｇｆｒ４阻害剤、その製造方法及び使用
HK40004140B (en) Fgfr4 inhibitor and preparation method and use thereof
HK40004140A (en) Fgfr4 inhibitor and preparation method and use thereof
HK40018495B (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
HK40018495A (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210610

R150 Certificate of patent or registration of utility model

Ref document number: 6898306

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250